In vivo discovery of blood-brain barrier opening small molecules with FishNAP

This study introduces FishNAP, a high-throughput zebrafish platform that enabled the discovery of FDA-approved small molecules capable of transiently and reversibly opening the blood-brain barrier, a mechanism validated in mice to facilitate improved central nervous system drug delivery.

The Gist

Imagine your brain is a highly secure, high-tech fortress. To keep the brain safe, it has a super-tight security gate called the Blood-Brain Barrier (BBB). This gate is so good at its job that it keeps out 98% of the drugs scientists try to use to treat brain diseases like Alzheimer's, Parkinson's, or brain tumors. It's like trying to mail a package to a fortress, but the guards at the gate refuse to let anything through, even if the package is medicine that could save a life.

For a long time, scientists have struggled to find a way to temporarily open this gate just enough to let the medicine in, without letting the bad stuff (toxins) in or breaking the gate permanently.

Here is how this new paper solves that problem, explained simply:

1. The Problem with Old Methods

Previously, to test if a drug could open the gate, scientists had to use tiny, slow, and expensive methods.

• The "Microscope" Problem: They often had to inject tiny amounts of dye into fish or mice and then look at them under a fancy microscope. This is like trying to check if a castle gate is open by sending one spy at a time, waiting for them to walk through, and then taking a photo. It's too slow to test thousands of potential keys.
• The "Lab Dish" Problem: They also tried testing drugs on cells in a dish. But cells in a dish are like actors on a stage without a real set; they don't behave the same way as cells inside a living, breathing body.

2. The New Solution: "FishNAP"

The researchers created a new tool called FishNAP. Think of this as a "Sleepy Fish Test."

• The Setup: They use baby zebrafish (tiny, transparent fish). These fish are perfect because they are small, cheap, and you can drop medicine right into the water they swim in.
• The Trick: They use a specific drug called loperamide (the same stuff used to stop diarrhea in humans).
  • Normal Fish: If the fish's "gate" (BBB) is working perfectly, the loperamide stays outside the brain. The fish stays awake, swims around, and is active.
  • Leaky Fish: If a test drug successfully pokes a hole in the gate, the loperamide sneaks inside the brain. Once inside, it acts like a sedative. The fish gets sleepy, stops swimming, and "naps."
• The Magic: Instead of looking at one fish under a microscope for hours, they put up to seven fish in a single cup (a 96-well plate) and use a camera to watch how much they move. If the fish are napping, the gate is open! This lets them test thousands of drugs in a matter of weeks instead of years.

3. The Treasure Hunt

Using FishNAP, the scientists tested 2,320 different drugs that are already approved by the FDA for other uses (like heart medicine, cancer drugs, or vitamins). They were looking for the "keys" that could open the brain gate.

• The Results: They found 11 drugs that made the fish sleepy, meaning they opened the gate.
• The Best Keys: They narrowed it down to 7 drugs that were the most effective. Some of these were surprising, like Calcitriol (a form of Vitamin D) and Lovastatin (a common cholesterol drug).
• The Safety Check: The most important part? The gate didn't stay broken. After the drug wore off (within 24 hours), the fish's gate closed back up and worked normally again. This is crucial because you want to open the door just long enough to let the medicine in, then close it immediately to keep the brain safe.

4. Does it Work on Mammals?

Zebrafish are great, but humans are mammals, not fish. So, the scientists took the top three candidates (Vitamin D, Cholesterol drug, and a cancer drug) and tested them on adult mice.

• The Result: It worked! The drugs opened the mouse brain barrier, allowing a tracer dye to leak into the brain.
• The Mechanism: They found that these drugs worked by loosening the "mortar" (a protein called Claudin-5) that holds the bricks of the barrier together.

Why This Matters

This paper is a game-changer because:

1. Speed: They found these drugs in less than three months using a method that is fast and cheap.
2. Repurposing: They didn't have to invent new drugs from scratch; they found existing, safe drugs that can do something new.
3. Hope: This gives us a potential way to treat brain diseases that are currently impossible to cure because the medicine can't get inside.

In a nutshell: The scientists built a "sleepy fish" test to quickly find existing drugs that can temporarily unlock the brain's front door, letting life-saving medicine inside, and then locking it back up again. It's like finding a master key that fits the brain's security system without breaking the lock.

Technical Summary

1. Problem Statement

The blood-brain barrier (BBB) is a critical physiological structure that maintains neural homeostasis by tightly regulating molecular exchange between the circulation and the brain. While essential for neuroprotection, the BBB acts as a formidable obstacle for treating neurological disorders, preventing over 98% of small-molecule drugs from reaching the central nervous system (CNS).

Current strategies to overcome this include chemical drug modification, receptor-mediated transport, and focused ultrasound. However, the systematic discovery of small molecules that can safely and reversibly open the intact BBB is hindered by limitations in existing screening platforms:

• In vitro models (e.g., transwell assays, organ-on-chip) lack the complex cellular interactions (endothelial-pericyte-astrocyte signaling) and hemodynamic forces of the intact brain, leading to a loss of BBB molecular signatures and poor translation to in vivo efficacy.
• Existing in vivo zebrafish assays rely on invasive tracer injections and high-resolution confocal imaging, which are low-throughput, time-consuming, and difficult to scale for large chemical libraries.

2. Methodology: The FishNAP Platform

The authors developed FishNAP (Fish-based assay for Non-invasive Assessment of Permeability), a high-throughput, non-invasive zebrafish platform designed to screen for BBB modulators in a 96-well format.

• Mechanism of Action: The assay utilizes loperamide, a synthetic opioid agonist that does not cross an intact BBB.
  • Intact BBB: Larvae remain behaviorally active despite loperamide exposure.
  • Leaky BBB: If the barrier is compromised, loperamide enters the brain, binds to opioid receptors, and induces sedation (reduced locomotor activity).
• Workflow:
  1. Larval zebrafish are treated with compounds in a 96-well plate.
  2. Loperamide is added, and locomotor activity is recorded for 1 hour using the Daniovision system.
  3. An "activity ratio" (final 20 mins / initial 20 mins) is calculated. A ratio < 0.6 indicates BBB opening.
• Advantages: The assay is non-lethal, requires no microinjection or confocal imaging, and can be completed in under one hour, enabling rapid screening of large libraries.

3. Key Contributions

• Development of FishNAP: A scalable, behavioral assay that correlates BBB permeability with locomotor sedation, validated against developmental stages (3 vs. 5–7 days post-fertilization) and genetic mutants (spock1 and cldn5a crispants).
• Large-Scale Chemical Screening: The first systematic screen of 2,320 FDA-approved small molecules using an in vivo BBB permeability assay.
• Discovery of Novel Modulators: Identification of 11 compounds that open the BBB, with 7 confirmed to allow entry of tracers of varying molecular weights.
• Cross-Species Validation: Demonstration that the identified mechanisms (specifically Calcitriol, Lovastatin, and Sunitinib) are conserved in adult mice, reducing Claudin-5 expression and increasing tracer leakage.

4. Key Results

A. Platform Validation

• Developmental Sensitivity: FishNAP correctly identified the BBB as "leaky" at 3 days post-fertilization (dpf) and "sealed" at 5 and 7 dpf.
• Genetic Validation: The assay detected BBB dysfunction in spock1 mutants (defective tight junctions) and cldn5a crispants (mosaic knockdown of Claudin-5).
• Efficiency: FishNAP detected BBB impairment in cldn5a crispants within 1 hour, compared to ~3 hours required for traditional tracer injection and confocal imaging. It also allowed for the stratification of mosaic knockdown efficiency based on behavioral phenotype.

B. Chemical Screen Results

• Screening: From 2,320 FDA-approved compounds, the authors identified 11 hits that reproducibly induced sedation (BBB opening) after 48 hours of treatment.
• Tracer Validation: Follow-up assays using 1 kDa (NHS Ester) and 10 kDa (Dextran) tracers confirmed that 7 compounds significantly increased BBB permeability:
  1. Calcifediol
  2. Calcitriol
  3. LDE-225 (Hedgehog inhibitor)
  4. Lonafarnib (Farnesyltransferase inhibitor)
  5. Lovastatin (HMG-CoA reductase inhibitor)
  6. Sunitinib (Multi-kinase RTK inhibitor)
  7. Trametinib (MEK/ERK inhibitor)
• Mechanism Differentiation:
  • Tight Junction Disruption Only: LDE-225 and Trametinib increased permeability to 1 kDa tracers but not 10 kDa tracers, suggesting specific tight junction defects.
  • Transcytosis/Tight Junction Disruption: Calcitriol, Calcifediol, and Sunitinib increased permeability to both 1 kDa and 10 kDa tracers, suggesting broader barrier disruption or increased transcytosis.
• Reversibility: All 7 compounds showed reversible BBB modulation. When washed out, barrier integrity recovered within 24 hours for most. For Calcitriol and Lovastatin, lower doses (0.05 µM and 0.25 µM, respectively) were identified that induced opening without causing irreversible damage.

C. Translational Potential (Mouse Studies)

• Three representative compounds (Calcitriol, Lovastatin, Sunitinib) were tested in adult mice.
• Results: All three significantly increased the leakage of a 550 Da NHS-biotin tracer into the brain parenchyma.
• Molecular Mechanism: Immunostaining revealed a significant reduction in endothelial Claudin-5 (CLDN5) expression in treated mice, confirming that the zebrafish-derived mechanisms translate directly to mammals.

5. Significance

• Bridging the In Vitro/In Vivo Gap: FishNAP provides a scalable, physiological context for drug discovery that overcomes the limitations of cell-based models, which often fail to predict in vivo BBB permeability.
• New Therapeutic Avenues: The identification of FDA-approved drugs (e.g., Calcitriol, Lovastatin) that can transiently open the BBB offers immediate translational potential for enhancing CNS drug delivery for neurological diseases.
• Novel Biology: The discovery that Vitamin D signaling (Calcitriol/Calcifediol) can acutely increase BBB permeability challenges previous assumptions that Vitamin D primarily stabilizes the barrier, suggesting a complex, context-dependent regulatory role.
• Scalability: The platform enables the rapid screening of genetic and chemical libraries, accelerating the discovery of BBB modulators that were previously undetectable due to throughput constraints.

In conclusion, FishNAP represents a paradigm shift in BBB research, moving from low-throughput, invasive imaging to high-throughput, behavioral phenotyping, successfully identifying a new class of reversible, small-molecule BBB openers with conserved mechanisms across vertebrates.